A fusion peptide in preS1 and the human protein-disulfide isomerase ERp57 are involved in HBV membrane fusion process

  1. Jimena Pérez-Vargas
  2. Elin Teppa
  3. Fouzia Amirache
  4. Bertrand Boson
  5. Rémi Pereira de Oliveira
  6. Christophe Combet
  7. Anja Böckmann
  8. Floriane Fusil
  9. Natalia Freitas  Is a corresponding author
  10. Alessandra Carbone  Is a corresponding author
  11. François-Loïc Cosset  Is a corresponding author
  1. École normale supérieure de Lyon, France
  2. Sorbonne Université, France
  3. Centre International de Recherche en Infectiologie, France
  4. Cancer Research Center of Lyon (CRCL), France
  5. University of Lyon, France
  6. Sorbonne Universités, UPMC Univ. Paris 06, France

Abstract

Cell entry of enveloped viruses relies on the fusion between the viral and plasma or endosomal membranes, through a mechanism that is triggered by a cellular signal. Here we used a combination of computational and experimental approaches to unravel the main determinants of hepatitis B virus (HBV) membrane fusion process. We discovered that ERp57 is a host factor critically involved in triggering HBV fusion and infection. Then, through modelling approaches, we uncovered a putative allosteric cross-strand disulfide (CSD) bond in the HBV S glycoprotein and we demonstrate that its stabilization could prevent membrane fusion. Finally, we identified and characterized a potential fusion peptide in the preS1 domain of the HBV L glycoprotein. These results underscore a membrane fusion mechanism that could be triggered by ERp57, allowing a thiol/disulfide exchange reaction to occur and regulate isomerization of a critical CSD, which ultimately leads to the exposition of the fusion peptide.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for figures 1-3, 5-7 and 9.

Article and author information

Author details

  1. Jimena Pérez-Vargas

    École normale supérieure de Lyon, Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Elin Teppa

    UMR 7238, Biologie Computationnelle et Quantitative, Sorbonne Université, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Fouzia Amirache

    École normale supérieure de Lyon, Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Bertrand Boson

    Centre International de Recherche en Infectiologie, Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Rémi Pereira de Oliveira

    École normale supérieure de Lyon, Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Christophe Combet

    U1052, Cancer Research Center of Lyon (CRCL), Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7348-3520
  7. Anja Böckmann

    Molecular Microbiology and Structural Biochemistry, University of Lyon, Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8149-7941
  8. Floriane Fusil

    École normale supérieure de Lyon, Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Natalia Freitas

    École normale supérieure de Lyon, Lyon, France
    For correspondence
    natalia.bezerra-de-freitas@ens-lyon.fr
    Competing interests
    The authors declare that no competing interests exist.
  10. Alessandra Carbone

    UMR 7238, Biologie Computationnelle et Quantitative, Sorbonne Universités, UPMC Univ. Paris 06, Paris, France
    For correspondence
    Alessandra.Carbone@lip6.fr
    Competing interests
    The authors declare that no competing interests exist.
  11. François-Loïc Cosset

    École normale supérieure de Lyon, Lyon, France
    For correspondence
    flcosset@ens-lyon.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8842-3726

Funding

ANRS (ECTZ160643)

  • François-Loïc Cosset

ANR (ANR-11-LABX-0048)

  • François-Loïc Cosset

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All experiments were performed in accordance with the European Union guidelines for approval of the protocols by the local ethics committee (Authorization Agreement C2EA-15, "Comité Rhône-Alpes d'Ethique pour l'Expérimentation Animale", Lyon, France - APAFIS#27316-2020060810332115 v4).

Reviewing Editor

  1. Mark Marsh, University College London, United Kingdom

Publication history

  1. Received: October 31, 2020
  2. Accepted: June 29, 2021
  3. Accepted Manuscript published: June 30, 2021 (version 1)
  4. Version of Record published: July 15, 2021 (version 2)

Copyright

© 2021, Pérez-Vargas et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,360
    Page views
  • 257
    Downloads
  • 6
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jimena Pérez-Vargas
  2. Elin Teppa
  3. Fouzia Amirache
  4. Bertrand Boson
  5. Rémi Pereira de Oliveira
  6. Christophe Combet
  7. Anja Böckmann
  8. Floriane Fusil
  9. Natalia Freitas
  10. Alessandra Carbone
  11. François-Loïc Cosset
(2021)
A fusion peptide in preS1 and the human protein-disulfide isomerase ERp57 are involved in HBV membrane fusion process
eLife 10:e64507.
https://doi.org/10.7554/eLife.64507

Further reading

    1. Cancer Biology
    2. Computational and Systems Biology
    Matthew Roberts, Julia Ogden ... Carlos Lopez-Garcia
    Tools and Resources Updated

    Lung squamous cell carcinoma (LUSC) is a type of lung cancer with a dismal prognosis that lacks adequate therapies and actionable targets. This disease is characterized by a sequence of low- and high-grade preinvasive stages with increasing probability of malignant progression. Increasing our knowledge about the biology of these premalignant lesions (PMLs) is necessary to design new methods of early detection and prevention, and to identify the molecular processes that are key for malignant progression. To facilitate this research, we have designed XTABLE (Exploring Transcriptomes of Bronchial Lesions), an open-source application that integrates the most extensive transcriptomic databases of PMLs published so far. With this tool, users can stratify samples using multiple parameters and interrogate PML biology in multiple manners, such as two- and multiple-group comparisons, interrogation of genes of interests, and transcriptional signatures. Using XTABLE, we have carried out a comparative study of the potential role of chromosomal instability scores as biomarkers of PML progression and mapped the onset of the most relevant LUSC pathways to the sequence of LUSC developmental stages. XTABLE will critically facilitate new research for the identification of early detection biomarkers and acquire a better understanding of the LUSC precancerous stages.

    1. Computational and Systems Biology
    2. Neuroscience
    Rebecca Elizabeth Carlisle, Arthur D Kuo
    Research Article Updated

    Humans make a number of choices when they walk, such as how fast and for how long. The preferred steady walking speed seems chosen to minimize energy expenditure per distance traveled. But the speed of actual walking bouts is not only steady, but rather a time-varying trajectory, which can also be modulated by task urgency or an individual’s movement vigor. Here we show that speed trajectories and durations of human walking bouts are explained better by an objective to minimize Energy and Time, meaning the total work or energy to reach destination, plus a cost proportional to bout duration. Applied to a computational model of walking dynamics, this objective predicts dynamic speed vs. time trajectories with inverted U shapes. Model and human experiment (N=10) show that shorter bouts are unsteady and dominated by the time and effort of accelerating, and longer ones are steadier and faster and dominated by steady-state time and effort. Individual-dependent vigor may be characterized by the energy one is willing to spend to save a unit of time, which explains why some may walk faster than others, but everyone may have similar-shaped trajectories due to similar walking dynamics. Tradeoffs between energy and time costs can predict transient, steady, and vigor-related aspects of walking.